Tackling Antimicrobial Resistance in the Shadow of COVID-19.
Tackling Antimicrobial Resistance in the Shadow of COVID-19.
复制标题
DOI：
10.1128/mbio.00473-21
复制
发表时间：
2021-08-31
期刊：
影响因子：
6.4
通讯作者：
Patel A
中科院分区：
文献类型：
--
作者：
Patel A
2019年冠状病毒病(新冠肺炎)大流行对持续抗击抗菌素耐药细菌感染的努力是一个挑战。随着我们对新冠肺炎病的更多了解和药物管理的演变，抗菌剂和抗生素的更多使用以及许多人口缺乏持续的医疗保健可能会产生持久的影响。在大流行期间，性传播感染一直被低估，而且往往是由一些最具耐药性的病原体引起的。在他们最近发表在mBio上的文章中，Parzych等人。(E.M.Parzych，S.Gulati，B.Zeng，M.A.Bah，等，mBio12：e00242-21,2021年，https://doi.org/10.1128/mBio.00242-21)专注于通过体内传递抗淋球菌DNA编码抗体来预防淋球菌感染，该抗体已被修改为增加补体激活。核酸方法具有高度的适应性，对于对抗AMR病原体的个性化策略可能是非常有益的。
The coronavirus disease 2019 (COVID-19) pandemic is a challenge for ongoing efforts to combat antimicrobial-resistant (AMR) bacterial infections. As we learn more about COVID-19 disease and drug stewardship evolves, there is likely to be a lasting impact of increased use of antimicrobial agents and antibiotics, as well as a lack of consistent access to health care across many populations. Sexually transmitted infections have been underreported during the pandemic and are often caused by some of the most drug-resistant pathogens. In their recent article in mBio, Parzych et al. (E. M. Parzych, S. Gulati, B. Zheng, M. A. Bah, et al., mBio 12:e00242-21, 2021, https://doi.org/10.1128/mBio.00242-21) focus on protection against Neisseria gonorrhoeae infection via in vivo delivery of an antigonococcal DNA-encoded antibody that has been modified for increased complement activation. Nucleic acid approaches are highly adaptable and could be tremendously beneficial for personalized strategies to combat AMR pathogens.